Results 181 to 190 of about 55,874 (301)

An Evaluation of P Wave Dispersion, QT, Corrected QT and Corrected QT Dispersion Intervals on the Electrocardiograms of Malnourished Adults [PDF]

, 2010
Volkan Hancı, Hilal Ayoğlu, Serhan Yurtlu, Nesligül Yıldırım, Rahşan Dilek Okyay, Gülay Erdoğan Kayhan, E. Sayın, İşil Özkoçak Turan   +7 more
openalex   +1 more source

Alternative Pathway for Methyl Supply through the Coupling of SHMT1 and PEMT to Maintain Astrocytic Homeostasis in Parkinson's Disease

Advanced Science, Volume 13, Issue 7, 3 February 2026.
In Parkinson's disease, SHMT1 downregulation disrupts its interaction with PEMT in astrocytes, reducing SAM levels. This leads to H3K4me1 hypomethylation and decreased Slc1a2/Glul expression, ultimately exacerbating neuroexcitotoxicity and dopaminergic neuron loss.
Yue‐Han Chen, Rong‐Xin Zhu, Nuo‐Xi Zhang, Ting‐Ting Sun, Xi‐Wei Zhang, Yu‐Jie Zhao, Ben‐Yu He, Hang Yao, Ren‐Hong Du, Lei Cao, Wen‐Bin Zhang, Wei‐Guo Liu, Yun Cai, Cong Wang, Gang Hu, Yao Wei, Yang Liu, Ming Lu   +17 more
wiley   +1 more source

Evaluation of Corrected QT Intervals of 74 COVID19 Patients Treated with Hydroxychloroquine in Combination with or without Azithromycin and/or Favipiravir

, 2021
Oğuz Abdullah Uyaroğlu, Yusuf Ziya Şener, Murat Özdede, Nursel Çalık Başaran, Lale Özışık, Taha Koray Şahin, Uğur Canpolat, Ahmet Çağkan İnkaya, Hikmet Yorgun, Gülay Sain Güven, Kudret Aytemir   +10 more
openalex   +2 more sources

A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG‐055009, a novel thyroid hormone receptor beta (THR‐β) agonist for metabolic dysfunction‐associated steatohepatitis (MASH), in healthy participants

Clinical Pharmacology in Drug Development, Volume 15, Issue 2, February 2026.
Abstract ALG–055009 is an oral thyroid hormone receptor beta (THR‐β) agonist being evaluated for treating metabolic dysfunction–associated steatohepatitis (MASH). This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALG‐055009 and bioavailability/food effect.
Hakim Charfi, Benedetta Massetto, Megan Fitzgerald, Kha Le, Stanley Wang, Ifong Kan‐Eng, Meenakshi Venkatraman, Naqvi Mohammad, Lawrence Blatt, Tse‐I Lin, Sushmita M. Chanda, John Fry   +11 more
wiley   +1 more source

Nonalcoholic Fatty Liver Disease Is Related to Abnormal Corrected QT Interval and Left Ventricular Hypertrophy in Chinese Male Steelworkers. [PDF]

Int J Environ Res Public Health, 2022
Hung WC, Yu TH, Wu CC, Lee TL, Tang WH, Chen CC, Lu IC, Chung FM, Lee YJ, Hsu CC.   +9 more
europepmc   +1 more source

Large‐Scale Analysis of Age and Sex Effects on Corrected QT and JT Intervals: Insights From Hospital‐Based Controls and Moxifloxacin‐Treated Cases [PDF]

Eunwoo Kim, Hyun Young Lee, Young‐Min Ye, Anhye Kim   +3 more
openalex   +1 more source

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

Clinical Pharmacology in Drug Development, Volume 15, Issue 2, February 2026.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch, Wendy Weis, Felix Huth, Seshulatha Jamalapuram, Michelle Quinlan, Amarnath Bandaru, Suleyman Eralp Bellibas, Asmae Mirkou, Shruti Kapoor, Shefali Kakar   +9 more
wiley   +1 more source

The association between nonalcoholic fatty liver disease and corrected QT interval prolongation among generally healthy Iranian population: Fasa Cohort Study (FACS). [PDF]

Clin Cardiol, 2023
Naderi A, Farjam M, Mojarrad Sani M, Abdollahi A, Alkamel A, Keshavarzian O, Tabrizi R.   +6 more
europepmc   +1 more source

Evaluation of clinical cardiac safety of zilurgisertib, an activin receptor‐like kinase‐2 (ALK2) inhibitor, in healthy participants

Clinical Pharmacology in Drug Development, Volume 15, Issue 2, February 2026.
Abstract The oral, small molecule inhibitor of activin receptor‐like kinase‐2, zilurgisertib (INCB000928), is under evaluation in fibrodysplasia ossificans progressiva. Cardiac safety was assessed using electrocardiogram (ECG) parameters and a plasma concentration‐heart rate‐corrected QT (C‐QTc) interval analysis of pooled data from single ascending ...
Yan‐ou Yang, Hong Yang, Xing Liu, Xiaohua Gong, Jay Getsy, Kevin Rockich   +5 more
wiley   +1 more source

Corrected QT interval prolongation after ganglionated plexus ablation: myth or reality?-Authors' reply. [PDF]

Europace, 2021
Hermans BJM, Zink MD, Rosmalen FV, Crijns HJGM, Vernooy K, Postema P, Pison L, Schotten U, Delhaas T.   +8 more
europepmc   +1 more source